Turn Therapeutics Topical Atopic Dermatitis Candidate Significantly Inhibits Key Cytokines in Expansion Study of Flagship Formula
Turn Therapeutics announced positive data results of GX-03, showing significant inhibition of key cytokines in an eczema model, with a 67.7% reduction in IL-31 levels vs placebo. The candidate also demonstrated a significant reduction in ISGA score to 0.8, indicating clear to almost clear skin condition.
Highlighted Terms
Related News
Turn Therapeutics Topical Atopic Dermatitis Candidate Significantly Inhibits Key Cytokines in Expansion Study of Flagship Formula
Turn Therapeutics announced positive data results of GX-03, showing significant inhibition of key cytokines in an eczema model, with a 67.7% reduction in IL-31 levels vs placebo. The candidate also demonstrated a significant reduction in ISGA score to 0.8, indicating clear to almost clear skin condition.